MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent literature suggests that HC synergizes with buthionine sulfoximine (BSO), a glutathione synthesis inhibitor to eliminate chronic myeloid leukemic (CML) cells through the GSH-ROS-JNK-ERK-iNOS mediated pathway (Chowdhury et al., 2013) and reports have suggested that HC may be developed as a single-agent chemotherapeutic drug or as an adjuvant (Gundala et al., 2014).